Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY® study

Fig. 3

‘Highly relevant’ reasons for choosing T2D study medications A by HCP specialty B by treatment (Prescribed Patient Set). AE, adverse event; CV, cardiovascular; DPP4i, dipeptidyl peptidase-4 inhibitor; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated haemoglobin; HCP, healthcare professional; SGLT2i, sodium-glucose cotransporter-2 inhibitor; T2D, type 2 diabetes

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840